-
Je něco špatně v tomto záznamu ?
Comparison of Presentation, Treatment, and Outcomes of Venous Thromboembolism in Long-Term Immobile Patients Based on Age
I. Weinberg, IY. Elgendy, AB. Dicks, PJ. Marchena, R. Malý, I. Francisco, JM. Pedrajas, C. Font, L. Hernández-Blasco, M. Monreal, RIETE Investigators
Jazyk angličtina Země Spojené státy americké
Typ dokumentu pozorovací studie, časopisecké články
NLK
Free Medical Journals
od 1997 do Před 1 rokem
PubMed Central
od 1997 do Před 1 rokem
Europe PubMed Central
od 1997 do Před 1 rokem
ProQuest Central
od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 1998-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 1997-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
Health Management Database (ProQuest)
od 1997-01-01 do Před 1 rokem
- MeSH
- antikoagulancia škodlivé účinky MeSH
- krvácení chemicky indukované epidemiologie komplikace MeSH
- lidé MeSH
- plicní embolie * diagnóza epidemiologie terapie MeSH
- recidiva MeSH
- registrace MeSH
- senioři MeSH
- žilní tromboembolie * diagnóza farmakoterapie epidemiologie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
BACKGROUND: Chronic immobility is prevalent, especially as people age. However, little is known about venous thromboembolism (VTE) outcomes in this population. OBJECTIVE: To compare the presentation, treatment, and outcomes in chronically immobile (>8 weeks) patients older vs. younger than 75 who presented with VTE. DESIGN: An observational international registry of patients with VTE. PARTICIPANTS: Patients with acute VTE from the "Registro Informatizado Enfermedad TromboEmbolica" (RIETE) registry who were chronically immobile. MAIN MEASURES: Baseline characteristics, presenting signs and symptoms, treatment and outcomes including major bleeding, recurrent VTE, and mortality. KEY RESULTS: Among 4612 immobile patients (mean age 75.7 years, 34% male), 2127 (46%) presented with pulmonary embolism (PE). Patients >75 years presented more often with dyspnea (44% vs. 38%) or altered mental status (23% vs. 8.1%) and less often with chest pain (13% vs. 18%). The median duration of anticoagulation was shorter in older compared with younger patients [126 vs. 169 days]. During the first 90 days of anticoagulation, major bleeding (4.0% vs. 2.2%), PE-related death (2.5% vs. 1.1%), and bleeding-related death (0.78% vs. 0.26%) occurred more frequently among older patients. In 3550 patients who received anticoagulation beyond 90 days, older patients had more major bleeding [4.23 vs. 2.21 events per 100 patient years]. After anticoagulation discontinuation, recurrent VTE and major bleeding occurred in 11.8 and 9.25 and 1.49 and 0.69 events per 100 patient years, respectively, both in similar rates in both groups. In multivariable analysis, after stopping anticoagulation, VTE recurrence was inversely associated with long-term facility residence [OR 0.51 (0.28-0.92)], anemia [OR 0.63 (0.42-0.95)], and anticoagulation duration < 90 days [OR 0.38 (0.27-0.54)]. CONCLUSIONS: Chronically immobilized patients older than 75 years presenting with VTE experience a high rate of adverse events including major bleeding and recurrent VTE. When considering treatment beyond 90 days, we should account for bleeding, recurrence risk, and associated mortality.
Department of Internal Medicine Hospital Clínico San Carlos Madrid Spain
Department of Internal Medicine Hospital Universitari de Girona Dr Josep Trueta Girona Spain
Department of Medical Oncology Hospital Clínic Barcelona Spain
Department of Pneumonology Hospital General Universitario de Alicante ISABIAL UMH Alicante Spain
Department of Vascular Surgery Prisma Health USC School of Medicine Greenville Greenville SC USA
Division of Cardiovascular Medicine Gill Heart Institute University of Kentucky Lexington KY USA
Faculty of Health Sciences UCAM Universidad Católica San Antonio de Murcia Murcia Spain
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23011301
- 003
- CZ-PrNML
- 005
- 20230801132937.0
- 007
- ta
- 008
- 230718s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11606-023-08058-x $2 doi
- 035 __
- $a (PubMed)36750505
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Weinberg, Ido $u Vascular Medicine, Cardiology Division, Massachusetts General Hospital, 55 Fruit Street, GRB-852G, Boston, MA, 02114, USA. iweinberg@mgh.harvard.edu $1 https://orcid.org/0000000346335132
- 245 10
- $a Comparison of Presentation, Treatment, and Outcomes of Venous Thromboembolism in Long-Term Immobile Patients Based on Age / $c I. Weinberg, IY. Elgendy, AB. Dicks, PJ. Marchena, R. Malý, I. Francisco, JM. Pedrajas, C. Font, L. Hernández-Blasco, M. Monreal, RIETE Investigators
- 520 9_
- $a BACKGROUND: Chronic immobility is prevalent, especially as people age. However, little is known about venous thromboembolism (VTE) outcomes in this population. OBJECTIVE: To compare the presentation, treatment, and outcomes in chronically immobile (>8 weeks) patients older vs. younger than 75 who presented with VTE. DESIGN: An observational international registry of patients with VTE. PARTICIPANTS: Patients with acute VTE from the "Registro Informatizado Enfermedad TromboEmbolica" (RIETE) registry who were chronically immobile. MAIN MEASURES: Baseline characteristics, presenting signs and symptoms, treatment and outcomes including major bleeding, recurrent VTE, and mortality. KEY RESULTS: Among 4612 immobile patients (mean age 75.7 years, 34% male), 2127 (46%) presented with pulmonary embolism (PE). Patients >75 years presented more often with dyspnea (44% vs. 38%) or altered mental status (23% vs. 8.1%) and less often with chest pain (13% vs. 18%). The median duration of anticoagulation was shorter in older compared with younger patients [126 vs. 169 days]. During the first 90 days of anticoagulation, major bleeding (4.0% vs. 2.2%), PE-related death (2.5% vs. 1.1%), and bleeding-related death (0.78% vs. 0.26%) occurred more frequently among older patients. In 3550 patients who received anticoagulation beyond 90 days, older patients had more major bleeding [4.23 vs. 2.21 events per 100 patient years]. After anticoagulation discontinuation, recurrent VTE and major bleeding occurred in 11.8 and 9.25 and 1.49 and 0.69 events per 100 patient years, respectively, both in similar rates in both groups. In multivariable analysis, after stopping anticoagulation, VTE recurrence was inversely associated with long-term facility residence [OR 0.51 (0.28-0.92)], anemia [OR 0.63 (0.42-0.95)], and anticoagulation duration < 90 days [OR 0.38 (0.27-0.54)]. CONCLUSIONS: Chronically immobilized patients older than 75 years presenting with VTE experience a high rate of adverse events including major bleeding and recurrent VTE. When considering treatment beyond 90 days, we should account for bleeding, recurrence risk, and associated mortality.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a žilní tromboembolie $x diagnóza $x farmakoterapie $x epidemiologie $7 D054556
- 650 _2
- $a antikoagulancia $x škodlivé účinky $7 D000925
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a krvácení $x chemicky indukované $x epidemiologie $x komplikace $7 D006470
- 650 12
- $a plicní embolie $x diagnóza $x epidemiologie $x terapie $7 D011655
- 650 _2
- $a registrace $7 D012042
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Elgendy, Islam Y $u Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY, USA
- 700 1_
- $a Dicks, Andrew B $u Department of Vascular Surgery, Prisma Health/USC School of Medicine Greenville, Greenville, SC, USA
- 700 1_
- $a Marchena, Pablo J $u Department of Internal Medicine and Emergency, Parc Sanitari Sant Joan de Déu-Hospital General, Barcelona, Spain
- 700 1_
- $a Malý, Radovan $u Department of Cardiovascular Medicine I, Charles University in Prague, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Francisco, Iria $u Department of Internal Medicine, Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain
- 700 1_
- $a Pedrajas, José M $u Department of Internal Medicine, Hospital Clínico San Carlos, Madrid, Spain
- 700 1_
- $a Font, Carme $u Department of Medical Oncology, Hospital Clínic, Barcelona, Spain
- 700 1_
- $a Hernández-Blasco, Luis $u Department of Pneumonology, Hospital General Universitario de Alicante, ISABIAL, UMH, Alicante, Spain
- 700 1_
- $a Monreal, Manuel $u Faculty of Health Sciences, UCAM - Universidad Católica San Antonio de Murcia, Murcia, Spain
- 710 2_
- $a RIETE Investigators
- 773 0_
- $w MED00007267 $t Journal of general internal medicine $x 1525-1497 $g Roč. 38, č. 8 (2023), s. 1877-1886
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36750505 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132934 $b ABA008
- 999 __
- $a ok $b bmc $g 1963603 $s 1197566
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 38 $c 8 $d 1877-1886 $e 20230207 $i 1525-1497 $m Journal of general internal medicine $n J Gen Intern Med $x MED00007267
- LZP __
- $a Pubmed-20230718
